BRISTOL-MYERS SQUIBB COMPANY Deferred Revenue and Credits, Noncurrent
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Deferred Revenue and Credits, Noncurrent of $448.00 million as of 2019-03-31, per its 10-Q filed 2019-04-25.
Discontinued › Notes › ASU 2014-09 Transition
us-gaap:DeferredRevenueAndCreditsNoncurrent · last filed 2019-04-25
- 2019-03-31: Deferred Revenue and Credits, Noncurrent $448.00M.
- 2018-12-31: Deferred Revenue and Credits, Noncurrent $468.00M.
- 2018-09-30: Deferred Revenue and Credits, Noncurrent $486.00M.
- 2018-06-30: Deferred Revenue and Credits, Noncurrent $501.00M.
| Period end | Deferred Revenue and Credits, Noncurrent |
|---|---|
| 2019-03-31 | $448.00M 10-Q · filed 2019-04-25 |
| 2018-12-31 | $468.00M 10-Q · filed 2019-04-25 |
| 2018-09-30 | $486.00M 10-Q · filed 2018-10-25 |
| 2018-06-30 | $501.00M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $447.00M 10-Q · filed 2018-04-26 |
| 2017-12-31 | $454.00M 10-K · filed 2019-02-25 |
| 2017-09-30 | $492.00M 10-Q · filed 2017-10-26 |
| 2017-06-30 | $512.00M 10-Q · filed 2017-07-27 |
| 2017-03-31 | $528.00M 10-Q · filed 2017-04-27 |
| 2016-12-31 | $547.00M 10-K · filed 2018-02-13 |
| 2016-09-30 | $567.00M 10-Q · filed 2016-10-27 |
| 2016-06-30 | $586.00M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $606.00M 10-Q · filed 2016-04-28 |
| 2015-12-31 | $586.00M 10-K · filed 2017-02-21 |
| 2015-09-30 | $630.00M 10-Q · filed 2015-10-27 |
| 2015-06-30 | $667.00M 10-Q · filed 2015-07-23 |
| 2015-03-31 | $697.00M 10-Q · filed 2015-04-28 |
| 2014-12-31 | $770.00M 10-K · filed 2016-02-12 |
| 2014-09-30 | $810.00M 10-Q · filed 2014-10-24 |
| 2014-06-30 | $1.04B 10-Q · filed 2014-07-24 |
| 2014-03-31 | $1.06B 10-Q · filed 2014-04-29 |
| 2013-12-31 | $769.00M 10-K · filed 2015-02-13 |
| 2013-09-30 | $4.20B 10-Q · filed 2013-10-23 |
| 2013-06-30 | $4.15B 10-Q · filed 2013-07-25 |
| 2013-03-31 | $4.10B 10-Q · filed 2013-04-25 |
| 2012-12-31 | $4.02B 10-K · filed 2014-02-14 |
| 2012-09-30 | $4.01B 10-Q · filed 2012-10-24 |
| 2012-06-30 | $805.00M 10-Q · filed 2012-07-25 |
| 2012-03-31 | $836.00M 10-Q · filed 2012-04-26 |
| 2011-12-31 | $866.00M 10-K · filed 2013-02-15 |
| 2011-09-30 | $860.00M 10-Q · filed 2011-10-27 |
| 2011-06-30 | $923.00M 10-Q · filed 2011-07-28 |
| 2010-12-31 | $895.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |